Hims & Hers Health, Inc. $HIMS Holdings Raised by Candriam S.C.A.

Candriam S.C.A. increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 245.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 306,273 shares of the company’s stock after purchasing an additional 217,493 shares during the period. Candriam S.C.A.’s holdings in Hims & Hers Health were worth $17,372,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its position in shares of Hims & Hers Health by 44.7% in the 3rd quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock worth $54,000 after buying an additional 283 shares during the last quarter. Renaissance Group LLC raised its stake in Hims & Hers Health by 5.4% during the third quarter. Renaissance Group LLC now owns 185,972 shares of the company’s stock worth $10,548,000 after acquiring an additional 9,588 shares during the period. State of Michigan Retirement System lifted its holdings in Hims & Hers Health by 49.2% in the third quarter. State of Michigan Retirement System now owns 2,057,700 shares of the company’s stock worth $116,713,000 after acquiring an additional 678,600 shares during the last quarter. Waterloo Capital L.P. acquired a new position in Hims & Hers Health in the third quarter valued at approximately $221,000. Finally, BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of Hims & Hers Health by 1.5% during the third quarter. BI Asset Management Fondsmaeglerselskab A S now owns 107,215 shares of the company’s stock valued at $6,081,000 after purchasing an additional 1,537 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insiders Place Their Bets

In related news, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $258,952.34. Following the transaction, the insider owned 6,175 shares in the company, valued at $226,684.25. This trade represents a 53.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $367,870.91. Following the completion of the sale, the insider owned 169,940 shares of the company’s stock, valued at $6,238,497.40. This trade represents a 5.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 129,337 shares of company stock valued at $4,651,648. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Stock Down 16.0%

Hims & Hers Health stock opened at $19.33 on Tuesday. Hims & Hers Health, Inc. has a 52 week low of $16.35 and a 52 week high of $72.98. The stock has a market cap of $4.40 billion, a price-to-earnings ratio of 35.80, a PEG ratio of 3.79 and a beta of 2.43. The company’s 50-day moving average price is $32.60 and its two-hundred day moving average price is $43.05. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67.

Hims & Hers Health announced that its Board of Directors has authorized a share buyback plan on Monday, November 17th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

Several brokerages recently issued reports on HIMS. Leerink Partners raised Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. KeyCorp initiated coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Evercore assumed coverage on shares of Hims & Hers Health in a report on Monday, January 12th. They set an “in-line” rating and a $33.00 price target for the company. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus target price of $39.96.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: HIMS halted the compounded semaglutide pill after the FDA and industry pushback, a move management says follows “constructive conversations” that may reduce immediate regulatory exposure. Hims & Hers is scrapping its plan for a knockoff pill
• Neutral Sentiment: Some analysts/commentators argue the market has overreacted because HIMS’ business is broader than GLP-1s (weight-loss revenue estimated at ~30% of 2025), suggesting potential buying opportunities if fundamentals hold. Seeking Alpha: Don’t Fall For The Hysteria
• Neutral Sentiment: Some market commentators call the sharp drop a “buy-the-dip” setup for longer-term investors if regulatory/legal risks stabilize. HIMS 22% Collapse Looks Like A ‘Buy The Dip’ Moment
• Negative Sentiment: Novo Nordisk filed a U.S. patent lawsuit alleging HIMS infringed patents on semaglutide products, seeking to block sales and recover damages — a direct legal threat to HIMS’ ability to re-enter this market. Reuters: Novo Nordisk opens new front with patent suit
• Negative Sentiment: The FDA signaled it will restrict access to active ingredients used to compound GLP‑1s, increasing regulatory enforcement risk for firms offering copycat products. CNBC: Novo Nordisk sues Hims & Hers
• Negative Sentiment: Analysts cut price targets and ratings (Citigroup to $16.50 sell; TD Cowen and BofA also lowered targets/ratings), reflecting weaker near-term forecasts and increasing downside risk. Benzinga: Analyst cuts
• Negative Sentiment: An investor fraud/derivative investigation invitation has been announced, adding potential legal/financial overhang. BusinessWire: Fraud investigation notice
• Negative Sentiment: Share price volatility and a move to 52‑week lows reflect investor concern over execution, management decisions and dependency on GLP‑1 related revenue. Fool: Hims drops on lawsuit and regulatory risk

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.